Snowden Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Snowden Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20	Closed	–	–	1859
2021 Q4	$0	Buy	+20	New	+$777	﹤0.01%	2135

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Snowden Capital Advisors's RPRX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 20 shares.

Snowden Capital Advisors first reported a position in RPRX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Snowden Capital Advisors reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 20 Royalty Pharma shares in Q1 2022.
Snowden Capital Advisors first reported a position in Royalty Pharma in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Royalty Pharma position peaked at $0 in Q4 2021.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.